The deal announced Friday tacks on to similar reduced price agreements the Trump administration has made with five other pharmaceutical companies. Read more
Forbes - Dec 19
Takeda Pharmaceutical Co., Ltd (NYSE:TAK) on Thursday announced positive topline results for the two pivotal Phase 3 studies of zasocitinib (TAK-279) for moderate-to-severe plaque psoriasis (PsO).DataThe studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoi... Read more
Benzinga - Dec 18
William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday.Analyst Lachlan Hanbury-Brown writes that the company's anti-IGF-1R franchise represents a meaningful advance compared to Amgen Inc.’s (NASDAQ:AMGN) Tepezza (teprotumumab-trbw) for thyroid eye disease (TED).... Read more
Benzinga - Dec 03
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.0% on an annualized basis producing an average annual return of 13.12%. Currently, Amgen has a market capitalization of $183.15 billion. Buying $100 In AMGN: If an ...Full story available on Benzinga.com Read more
Benzinga - Nov 25
The qualitative latest Research report (2025-2032) on the Nut Midline Carcinoma Treatment Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using Read more
Openpr.com - Nov 12
Coherent Market Insights has released a report titled "Smart Capsule Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032", which includes market percentage records and a thorough enterprise analysis. This report looks at the market's competition, geographic distribut... Read more
Openpr.com - Nov 12
Glucagon-like Peptide 1 (GLP-1) Analogues Market reached US$ 62.81 Billion in 2024 and is expected to reach US$ 299.08 Billion by 2033, growing at a CAGR of 17.6 % during the forecast period 2025-2033.DataM Intelligence has released its latest report Read more
Openpr.com - Nov 10
Amgen (NASDAQ:AMGN – Get Free Report) had its price objective boosted by Guggenheim from $288.00 to $305.00 in a research note issued on Thursday,MarketScreener reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. Guggenheim’s target price indicates a p... Read more
Markets Daily - Nov 07
Affiliated Managers Group (NYSE:AMG – Free Report) had its target price lifted by Barrington Research from $285.00 to $295.00 in a report issued on Tuesday,Benzinga reports. They currently have an outperform rating on the asset manager’s stock. Several other research analysts also recently commen... Read more
Defenseworld Net - Nov 05
With questions surrounding its gastric cancer drug, Amgen fills in some gaps. Read more
Stat - Oct 20
